

## 10-Year Financial / Non-Financial Data (For the fiscal years as of / ended March 31)

(Millions of yen)

	JGAAP						IFRS				
	2010	2011	2012	2013	2014	2015	2016	2017	2017	2018	2019
<b>Revenue</b>	883,086	847,105	848,548	743,851	713,286	764,671	804,578	748,050	740,557	786,497	<b>793,862</b>
<b>Selling, general and administrative (SG&amp;A) expenses</b>	347,125	349,306	348,287	343,121	367,011	398,889	430,773	414,855	397,697	426,596	<b>437,510</b>
Percentage of revenue (%)	39.3%	41.2%	41.0%	46.1%	51.5%	52.2%	53.5%	55.5%	53.7%	54.2%	<b>55.1%</b>
<b>Operating profit</b>	61,160	38,379	35,518	35,077	73,445	90,962	104,464	76,487	71,192	81,029	<b>28,281</b>
Percentage of revenue (%)	6.9%	4.5%	4.2%	4.7%	10.3%	11.9%	13.0%	10.2%	9.6%	10.3%	<b>3.6%</b>
<b>Profit (loss) before tax</b>	90,703	19,938	(9,495)	19,142	16,425	8,934	70,800	81,686	62,481	76,665	<b>20,117</b>
<b>Net income (loss) (JGAAP) / Profit (loss) attributable to owners of parent (IFRS)</b>	52,527	3,866	(48,985)	8,020	13,627	(8,737)	62,594	78,191	42,783	57,064	<b>8,147</b>
Percentage of revenue (%)	5.9%	0.5%	—	1.1%	1.9%	—	7.8%	10.5%	5.8%	7.3%	<b>1.0%</b>
<b>EBITDA margin*1 (%)</b>	13.3%	9.9%	9.5%	10.6%	16.8%	18.5%	19.2%	17.4%	16.9%	17.0%	<b>11.0%</b>
EBITDA margin (Medical Business)*2 (%)	29.2%	26.9%	26.6%	29.0%	29.7%	29.1%	29.5%	27.4%	27.4%	26.5%	<b>24.9%</b>
<b>R&amp;D expenditures</b>	61,850	67,286	61,356	63,379	66,796	74,101	81,415	79,178	79,178	89,469	<b>93,968</b>
Percentage of revenue (%)	7.0%	7.9%	7.2%	8.5%	9.4%	9.7%	10.1%	10.6%	10.7%	11.4%	<b>11.8%</b>
<b>Capital expenditures</b>	34,323	32,699	37,961	28,109	37,810	47,743	64,445	49,347	60,683	65,255	<b>66,830</b>
<b>Depreciation and amortization</b>	43,099	34,188	33,787	33,899	36,850	41,219	39,912	44,658	54,290	52,913	<b>58,669</b>
<b>Amortization of goodwill</b>	12,918	11,619	11,103	9,683	9,457	9,421	9,867	8,642	—	—	<b>—</b>
<b>Financial indicators</b>											
Total assets*3	1,104,528	1,019,160	966,526	960,239	1,027,475	1,081,551	1,000,614	991,062	960,032	978,663	<b>932,030</b>
Total net assets (JGAAP)*3 / Total equity (IFRS)	163,131	115,579	48,028	151,907	331,284	357,254	384,283	430,880	396,228	444,259	<b>442,387</b>
Equity ratio (JGAAP) / Ratio of equity attributable to owners of parent to total assets (IFRS) (%)	14.1%	11.0%	4.6%	15.5%	32.1%	32.9%	38.2%	43.3%	41.1%	45.2%	<b>47.3%</b>
Interest-bearing debt	661,481	648,787	642,426	560,390	415,831	354,421	321,138	286,357	285,970	247,974	<b>181,335</b>
Net debt	454,698	435,226	442,338	330,780	163,710	144,546	154,584	86,926	86,505	56,735	<b>66,909</b>
Inventories	89,959	92,929	102,493	99,307	98,595	107,387	111,558	124,064	125,319	139,309	<b>153,623</b>
Inventory turnover period (months)	1.3	1.3	1.4	1.6	1.7	1.6	1.6	1.9	2.0	2.1	<b>2.3</b>
Cash and cash equivalents at end of year	203,013	210,385	198,661	225,782	251,344	209,809	166,323	199,431	199,465	191,239	<b>114,563</b>
Cash flows from operating activities	76,245	30,469	30,889	25,233	72,388	66,811	48,621	90,194	102,052	95,146	<b>66,943</b>
Cash flows from investing activities	(20,967)	19,003	(35,735)	33,455	(20,273)	(39,612)	(52,897)	(8,305)	(20,814)	(53,312)	<b>(60,296)</b>
Cash flows from financing activities	17,355	(37,359)	(5,761)	(42,436)	(39,693)	(70,185)	(33,870)	(44,244)	(43,615)	(51,058)	<b>(82,948)</b>
Return on equity (ROE) (%)	40.6%	2.9%	(62.3%)	8.3%	5.7%	(2.6%)	17.0%	19.3%	11.3%	13.6%	<b>1.8%</b>
Return on assets (ROA) (%)	4.9%	0.4%	(4.9%)	0.8%	1.4%	(0.8%)	6.0%	7.9%	4.4%	5.9%	<b>0.9%</b>
Net income (loss) per share*4 (JGAAP) / Profit attributable to owners of parent per share (IFRS) (yen)	194.90	14.39	(183.54)	28.96	41.05	(25.53)	182.90	228.47	125.01	41.71	<b>5.97</b>
Total equity per share*4 (JGAAP) / Equity attributable to owners of parent per share (IFRS) (yen)	576.63	421.37	167.76	493.30	962.83	1,038.64	1,117.24	1,252.96	1,153.45	324.25	<b>323.06</b>
Price earnings ratio (PER)*5 (times)	15.4	160.8	—	76.4	80.2	—	23.9	18.7	34.2	24.2	<b>201.3</b>
Price book-value ratio (PBR) (times)	5.2	5.5	8.1	4.5	3.4	4.3	3.9	3.4	3.7	3.1	<b>3.7</b>
Outstanding market value (billions of yen)	813.8	627.7	367.3	675.8	1,127.4	1,530.0	1,499.2	1,466.6	1,466.6	1,384.5	<b>1,647.8</b>
Cash dividends per share (yen)	30	30	—	—	—	10	17	28	28	28	<b>30</b>
<b>Average exchange rate</b>											
U.S. dollar / Yen	92.85	85.72	79.08	83.10	100.24	109.93	120.14	108.38	108.38	110.85	<b>110.91</b>
Euro / Yen	131.15	113.12	108.98	107.14	134.37	138.77	132.58	118.79	118.79	129.70	<b>128.41</b>
<b>Non-financial indicators</b>											
Number of employees*6	35,376	34,391	34,112	30,697	30,702	31,540	33,336	34,687	34,687	35,933	<b>35,124</b>
(Average number of temporary employees)	(—)	(5,336)	(5,009)	(2,240)	(2,978)	(1,374)	(1,257)	(1,298)	(1,298)	(1,511)	<b>(1,396)</b>
Overseas employees as a percentage of employees (%)	63.3%	62.4%	62.1%	62.4%	62.5%	63.2%	63.3%	63.7%	63.7%	63.7%	<b>61.9%</b>
Percentage of women in management roles*7 (%)	0.9%	0.9%	0.8%	0.9%	1.0%	1.2%	1.4%	1.9%	1.9%	2.3%	<b>2.9%</b>
Percentage of employees with disabilities*8 (%)	1.8%	1.8%	1.9%	1.9%	2.0%	2.1%	1.9%	2.1%	2.1%	2.2%	<b>2.2%</b>

\*1 At the Company, EBITDA is calculated using the following assumptions: EBITDA = Operating profit + Depreciation and amortization that is included in cost of sales or SG&A expenses + Amortization of goodwill that is included in SG&A expenses

EBITDA margin = EBITDA / Revenue

\*2 At the Company, EBITDA (Medical Business) is calculated using the following assumptions: EBITDA = Segment profit in the Medical Business + Depreciation and amortization that is included in cost of sales or SG&A expenses + Amortization of goodwill that is included in SG&A expenses  
EBITDA margin (Medical Business) = EBITDA (Medical Business) / Revenue

\*3 In line with the issuance of IAS No. 19 "Employee Benefits" (revised on June 16, 2011) to be applied for fiscal years beginning on or after January 1, 2013, certain overseas subsidiaries adopted IAS No. 19 effective from the fiscal year ended March 31, 2014, and changed their method of recognizing actuarial gain or loss. This change has been applied retroactively to the March 31, 2013.

\*4 The Company conducted a stock split at the ratio of four shares for one ordinary share on April 1, 2019. "Profit attributable to owners of parent per share" is expressed with the figure after the stock split. The figure for fiscal 2018 is recalculated using the same method.

\*5 Price earnings ratio (PER) for the fiscal years ended March 31, 2012 and 2015 are omitted as Olympus recorded net loss for these fiscal years.

\*6 The average number of temporary employees is stated in parentheses from the fiscal year ended March 31, 2011, as the number of temporary employees is over 10% of the total number of employees.

\*7 Figures for percentage of women in management roles only include individuals in Japan.

\*8 Figures for percentage of employees with disabilities are as of June 1 of the respective year and only include individuals in Japan.